Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 248

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 248
---
 August 5, 2024 (as described in footnote 7), and the contribution will be made without issuing new shares. (b)Loans provided by the Parent to Heritas Argentina (including loans that had been granted as of June 30, 2024, disclosed in Note 19 to OmnigenicsAI’s combined financial statements as of that date and financings performed during the second semester of 2024, as described in Note 6 above) will be transferred to OmnigenicsAI, which will performed as an irrevocable in -kindcontribution to Heritas Argentina equivalent to the outstanding debt, including accrued interests as of the closing date. This contribution will result in a capital increase through the issuance of new shares of Heritas Argentina.

111

The effects of these in -kindcontributions on the Pro Forma Statement of Financial Position are as follows: •Decrease in current and non -currentloans by $47,693 and $712,561, respectively. •Increase of $760,254 in the Accumulated deficit because these in -kindcontributions from the Parent to OmnigenicsAI and Heritas Argentina will not imply the issuance of additional shares. (8)On August 11, 2024, OmnigenicsAI, the Parent, and MultiplAI signed a binding term sheet outlining the terms and conditions for a Reseller License Agreement to settle MultiplAI’s outstanding debt to the Parent, amounting to $395,260, due by February 2025. Under the agreement, MultiplAI will grant OmnigenicsAI exclusive rights to commercialize its proprietary blood -basedscreening tests in Latin America, along with providing 600 pre -paidtests for business development purposes. These exclusive rights are granted for a period of five years, commencing on January 1, 2025. The effects of this agreement in the pro forma financial information are as follows: (a)If this agreement had been signed on July 1, 2023, as of June 30, 2024, OmnigenicsAI would have recognized an intangible assets amortization of $31,052 disclosed in the “Selling expenses” line in the Pro forma Combined Consolidated Statement of Operations, considering a useful life of five years (see Note (2) under “ Adjustments to Unaudited Pro Forma Combined Consolidated Statement of Operations for the Year Ended June 30, 2024”). The intangible asset assumes a useful life of five years